One-Year Outcomes from the TAXUS Express Stent Versus Cypher Stent

We compared 1-year outcomes in patients treated with paclitaxel-eluting stents (PESs) or sirolimus-eluting stents (SESs) in “real-world” clinical practice. Clinical outcomes were evaluated in 1,558 consecutive, unselected, retrospectively collected patients treated with drug-eluting stents (DESs; PE...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2009-04, Vol.103 (7), p.930-936
Main Authors: Mayor, Manuel, MD, Malik, Amir Z., MD, Minor, Robert J., MD, Deshpande, Mahesh C., MS, MBA, Strauss, William E., MD, Maloney, Thomas H., MS, Baim, Donald S., MD, O'Neill, William, MD, Kandzari, David E., MD
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Phytogenic - pharmacology
Biological and medical sciences
Cardiology
Cardiology. Vascular system
Cardiovascular
Cardiovascular disease
Clinical medicine
Clinical outcomes
Coronary Angiography
Coronary Stenosis - diagnostic imaging
Coronary Stenosis - surgery
Drug-Eluting Stents
Female
Follow-Up Studies
Humans
Immunosuppressive Agents - pharmacology
Incidence
Kidney diseases
Male
Medical sciences
Middle Aged
Myocardial Revascularization - instrumentation
Paclitaxel - pharmacology
Postoperative Complications - epidemiology
Prosthesis Design
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Retrospective Studies
Sirolimus - pharmacology
Stents
Time Factors
Treatment Outcome
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We compared 1-year outcomes in patients treated with paclitaxel-eluting stents (PESs) or sirolimus-eluting stents (SESs) in “real-world” clinical practice. Clinical outcomes were evaluated in 1,558 consecutive, unselected, retrospectively collected patients treated with drug-eluting stents (DESs; PES = 816, SES = 742) at 19 United States centers. The primary end point was 1-year target vessel revascularization (TVR). The study included a prespecified diabetic cohort (PES = 289, SES = 247), for which efficacy comparisons between DESs were analyzed according to vessel diameter and presence of chronic kidney disease. Baseline demographic, angiographic, and procedural characteristics were similar between patients treated with PESs and those treated with SESs. At 1 year, there were no overall statistical differences in death, myocardial infarction, TVR, or stent thrombosis. In the diabetic cohort, however, the cumulative incidence of TVR was significantly lower for patients treated with PESs (3%) compared with SESs (9%, p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2008.11.052